TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03403231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
Study: NCT03779789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Antidepressant classified under the category other antidepressants according to the ATC/DDD index \[ATC=Anatomical Therapeutic Chemical Classification System; DDD=Defined Daily Dose\]. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-20 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 50-200 mg/day).
Study: NCT03403231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVENT Secure Messaging Intervention
Description: We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
Study: NCT01071200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)
Description: One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-hFSH
Description: One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
Study: NCT01146652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191 (REGN88)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT03779789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 10-20 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-10 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-40 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvoxamine
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 100-300 mg/day).
Study: NCT02499601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CORolla™ TAA device
Study: NCT01064466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETOPOSIDE - Usual
Description: Etoposide Injection
Study: NCT02088619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Therapy (QOLT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Healthy Education (HHE)
Study: NCT04735211

Intervention type: PROCEDURE
Intervention: Surgery
Description: Pediatric Surgery with hospitalized
Study: NCT01782976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: 2000 mg by vein twice weekly of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
Study: NCT02071420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Workstation Intervention
Description: Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ergonomic Intervention
Description: Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ergonomic Intervention
Description: Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Email Intervention
Description: Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email Intervention
Description: Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.
Study: NCT03411200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal and exercise-based intervention
Description: The multimodal and exercise-based intervention is comprised of:~1. Supervised and group-based exercise two times a week (60 minutes per session). The program consists of warm-up, exercises for balance and flexibility, progressive resistance training, and stretching and relaxation.~2. Individualized activity program based on step counts (with activity tracker). Based on each participant's starting point, preferences and motivation, an individualized program will be composed. Evaluation and goal-setting will be conducted once weekly.~3. Nurse-led supportive and motivational counseling; each participant will be invited to two sessions of counseling (in week 1 + 6). Each session will be based on a holistic assessment of each participant's life situation. Advice and counseling will be provided based on identified problems and needs.~4. A nutritional supplement (protein bar or drink) will be served to participants immediately after the supervised exercise session.
Study: NCT01527513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
Study: NCT01213849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50 mcg (4 inhalations)
Description: 4 inhalations of 50 mcg strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 mcg (4 inhalations)
Description: 4 inhalations of 100 mcg strength
Study: NCT01527513

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatments will be administered by oral route, once-daily, in the evening.
Study: NCT01384331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: 7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: 7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: 7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marvelon
Description: 7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days
Study: NCT02695823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.~Search of any neurological complication during the 5 postoperative days.
Study: NCT04092101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarettes with varying nicotine content
Description: 1) Altering the nicotine content of the tobacco research cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarettes with varying nicotine content
Description: 1) Altering the nicotine content of the tobacco research cigarette
Study: NCT01213849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 200 mcg (4 inhalations)
Description: 4 inhalations of 200 mcg strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol 25 mcg (4 inhalations)
Description: 4 inhalations of 25 mcg strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol 25 mcg (4 inhalations)
Description: 4 inhalations of 25 mcg strength
Study: NCT04092101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarettes with varying nicotine content
Description: 1) Altering the nicotine content of the tobacco research cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarettes with varying nicotine content
Description: 1) Altering the nicotine content of the tobacco research cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarettes
Description: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarettes
Description: 1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
Study: NCT00869531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wholegrain
Description: wholegrain wheat vs. refined wheat products
Study: NCT04458311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Supplied as 125 mg tablets
Study: NCT00869531

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: refined wheat
Description: refined wheat products
Study: NCT01493206

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy
Description: intraoperative radiotherapy
Study: NCT04458311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.
Study: NCT03696576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMST
Description: Training of the respiratory system muscles using the EMST device.
Study: NCT04512209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients will undergo an MR scan before undergoing cytoreductive surgery. If neoadjuvant chemotherapy is administered, an extra MR scan is planned before the start of the neoadjuvant chemotherapy.~During surgery, tissue samples will be taken for interstitial fluid pressure (IFP) measurement, immunohistochemistry (IHC) and characterization of biophysical properties (viscoelastic properties and hydraulic conductivity).
Study: NCT03388333

Intervention type: PROCEDURE
Intervention: Catheter Ablation

Intervention type: PROCEDURE
Intervention: Catheter Ablation
Study: NCT03696576

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PhoRTE
Description: Completing of PhoRTE voice therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PhoRTE
Description: Completing of PhoRTE voice therapy.
Study: NCT02299999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: Target: m-TOR
Study: NCT01137006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 1A)
Description: 5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 2A)
Description: 10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 3A)
Description: 20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 4A)
Description: 30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.
Study: NCT02480543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol (cytotec)
Study: NCT01137006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 1B)
Description: 10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 2B)
Description: 20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 3B)
Description: 30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.
Study: NCT01332006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrabone injection
Description: All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-bone cord blood hematopoietic stem cell transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-bone cord blood hematopoietic stem cell transplantation
Description: Intra-bone injection of CB hematopoietic SCs after conditioning regimen
Study: NCT00850135

Intervention type: DEVICE
Group type: OTHER
Intervention: The Seven Continuous Glucose Monitoring System
Description: Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
Study: NCT01064466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETOPOSIDE - Study
Description: Etoposide Capsule
Study: NCT01282957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive Group I
Description: Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive Group II
Description: Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
Study: NCT03245944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early Angioplasty
Description: Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Early means pt will get the procedure at 6 weeks from time of initiation of AVFs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: late Angioplasty
Description: Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Late means the angioplasty is done at 3 months from time of AVF creation if still immature at that time.
Study: NCT02640430

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 20 minutes, twice a day for 10 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free Aspire
Description: 20 minutes, twice a day for 10 sessions